Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC7 | O00311 | 6/20 | 0.46 |
| ▸ | DBF4 | Q9UBU7 | 2/20 | 0.46 |
| ▸ | JAK3 | P52333 | 8/20 | 0.42 |
| ▸ | JAK1 | P23458 | 5/20 | 0.42 |
| ▸ | JAK2 | O60674 | 3/20 | 0.42 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
| ▸ | LCK | P06239 | 1/20 | 0.37 |
| ▸ | BCHE | P06276 | 1/20 | 0.37 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.36 |
| ▸ | PIM1 | P11309 | 2/20 | 0.36 |
| ▸ | PRKACA | P17612 | 2/20 | 0.36 |
| ▸ | FLT3 | P36888 | 2/20 | 0.36 |
| ▸ | HIPK2 | Q9H2X6 | 2/20 | 0.36 |
| ▸ | PLK4 | O00444 | 1/20 | 0.36 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.36 |
| ▸ | INSR | P06213 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1267560 | 0.95 | CDC7 (0.39) | CDC7DBF4JAK3JAK1JAK2 | |
| SCHEMBL1266792 | 0.77 | MET (0.54) | CDC7DBF4JAK3JAK1JAK2 | |
| SCHEMBL878749 | 0.77 | CDC7 (0.48) | CDC7BCHEOPRL1OPRM1OPRK1 | |
| SCHEMBL1267592 | 0.76 | CDC7 (0.48) | CDC7DBF4JAK3JAK1JAK2 | |
| SCHEMBL1267952 | 0.74 | AXL (0.48) | CDC7BRD4MAP4K4PIM1PRKACA | |
| SCHEMBL21872984 | 0.74 | CDC7 (0.41) | CDC7JAK3BRD4MAP4K4PIM1 | |
| SCHEMBL24594035 | 0.74 | MAP2K1 (0.39) | JAK3JAK1JAK2BRD4PLK4 | |
| SCHEMBL1267562 | 0.73 | CDC7 (0.41) | CDC7DBF4BRD4OPRL1OPRM1 | |
| SCHEMBL1267104 | 0.71 | MET (0.54) | CDC7DBF4BCHESLC6A4CSF1R | |
| SCHEMBL26696379 | 0.71 | CDC7 (0.46) | CDC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170247370-A1 | COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR | PLEXXIKON INC. | 2017-08-31 | — | — | US | disclosed |
| US-9550768-B2 | Kinase modulation and indications therefor | PLEXXIKON INC. (US) | 2017-01-24 | — | — | US | disclosed |
| US-9487515-B2 | Compounds modulating c-fms and/or c-kit activity and uses therefor | PLEXXIKON INC. (US) | 2016-11-08 | — | — | US | disclosed |
| US-9169250-B2 | Compounds modulating c-fms and/or c-kit activity and uses therefor | PLEXXIKON INC. (US) | 2015-10-27 | — | — | US | disclosed |
| US-20150265586-A1 | COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR | DAIICHI SANKYO, INC. | 2015-09-24 | — | — | US | disclosed |
| US-20140243365-A1 | COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR | DAIICHI SANKYO, INC. | 2014-08-28 | — | — | US | disclosed |
| CN-103917235-A | Kinase modulation and indications therefor | PLEXXIKON INC | 2014-07-09 | — | — | CN | disclosed |
| US-8722702-B2 | Compounds modulating c-fms and/or c-kit activity and uses therefor | PLEXXIKON INC. (US) | 2014-05-13 | — | — | US | disclosed |
| EP-2709622-A2 | KINASE MODULATION AND INDICATIONS THEREFOR | PLEXXIKON INC. (US) | 2014-03-26 | — | — | EP | disclosed |
| US-20130274259-A1 | KINASE MODULATION AND INDICATIONS THEREFOR | DAIICHI SANKYO, INC. | 2013-10-17 | — | — | US | disclosed |
| US-8404700-B2 | Compounds modulating c-fms and/or c-kit activity and uses therefor | PLEXXIKON INC. (US) | 2013-03-26 | — | — | US | disclosed |
| US-20120309756-A1 | COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR | PLEXXIKON INC | 2012-12-06 | — | — | US | disclosed |
| WO-2012158957-A2 | KINASE MODULATION AND INDICATIONS THEREFOR | PLEXXIKON INC. (US) | 2012-11-22 | — | — | WO | disclosed |
| US-20110230482-A1 | COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY | PLEXXIKON INC. | 2011-09-22 | — | — | US | disclosed |
| US-20110166174-A1 | COMPOUNDS MODULATING C-KIT AND C-FMS ACTIVITY AND USES THEREFOR | PLEXXIKON, INC. | 2011-07-07 | — | — | US | disclosed |
| US-7893075-B2 | Compounds modulating c-fms and/or c-kit activity and uses therefor | PLEXXIKON, INC. (US) | 2011-02-22 | — | — | US | disclosed |
| US-7846941-B2 | Compounds modulating c-kit and c-fms activity and uses therefor | PLEXXIKON, INC. (US) | 2010-12-07 | — | — | US | disclosed |
| US-20090076046-A1 | Compounds modulating c-fms and/or c-kit activity and uses therefor | PLEXXIKON INC | 2009-03-19 | — | — | US | disclosed |
| CN-101223169-A | Pyrrolo [2, 3-b ] pyridine derivative protein kinase inhibitors | PLEXXIKON INC (US) | 2008-07-16 | — | — | CN | disclosed |
| US-20070032519-A1 | Compounds modulating c-kit and c-fms activity and uses therefor | PLEXXIKON, INC. | 2007-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130274259-A1 | KINASE MODULATION AND INDICATIONS THEREFOR | FLT3, MET, BTK | CDC7 403/4885DBF4 3779/4885JAK3 15/4885 |
| US-20140243365-A1 | COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR | KIT, FLT3, FLT1 | CDC7 280/4885DBF4 4215/4885JAK3 188/4885 |
| US-20170247370-A1 | COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR | KIT, FLT3, FLT1 | CDC7 280/4885DBF4 4215/4885JAK3 188/4885 |
| US-20090076046-A1 | Compounds modulating c-fms and/or c-kit activity and uses therefor | KIT, FLT3, FLT1 | CDC7 280/4885DBF4 4215/4885JAK3 188/4885 |
| US-20120309756-A1 | COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR | KIT, FLT3, FLT1 | CDC7 280/4885DBF4 4215/4885JAK3 188/4885 |
| US-20110166174-A1 | COMPOUNDS MODULATING C-KIT AND C-FMS ACTIVITY AND USES THEREFOR | KIT, FLT3, FLT1 | CDC7 129/4885DBF4 4152/4885JAK3 143/4885 |
| US-20110230482-A1 | COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY | KIT, FLT3, FER | CDC7 111/4885DBF4 3643/4885JAK3 171/4885 |
| US-20150265586-A1 | COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR | KIT, FLT3, FLT1 | CDC7 280/4885DBF4 4215/4885JAK3 188/4885 |
| US-20070032519-A1 | Compounds modulating c-kit and c-fms activity and uses therefor | KIT, FLT3, FLT1 | CDC7 129/4885DBF4 4152/4885JAK3 143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.